0001401914
false
Dare Bioscience, Inc.
0001401914
2023-07-04
2023-07-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 4, 2023
DARÉ
BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-36395 |
|
20-4139823 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
3655
Nobel Drive, Suite 260
San
Diego, CA 92122
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (858) 926-7655
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock |
|
DARE |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On
July 4, 2023, Daré Bioscience, Inc. (“Daré”), and an affiliate of Organon & Co., Organon International
GmbH (“Organon”), entered into an amendment (the “Amendment”) to the exclusive license agreement dated as of
March 31, 2022 between the parties. Under the Amendment, Organon will pay $1.0 million to Daré to reimburse Daré for PDUFA
fees and other manufacturing expenses and to support continued advancement of the development and commercialization of XACIATO, and the
amount payable by Organon to Daré following the first commercial sale of a licensed product in the United States was revised to
$1.8 million.
The
foregoing brief description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment,
a copy of which Daré intends to file with its quarterly report on Form 10-Q for the quarterly period ending September 30, 2023,
with certain private or confidential provisions or terms redacted.
Item 7.01 Regulation FD Disclosure.
On
July 5, 2023, Daré issued a press release announcing the Amendment, a copy of which is attached as Exhibit 99.1 to this report
and is incorporated herein by reference.
The
information in Item 7.01 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that Section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in
this Item 7.01 and in Exhibit 99.1 shall not be incorporated by reference into any filing with the Securities and Exchange Commission
(the “SEC”) made by Daré, whether made before or after the date hereof, regardless of any general incorporation language
in such filing.
Item 8.01 Other Events.
To
provide for continuity of supply to support the commercial launch of XACIATOTM in the United States, additional manufacturing
related activities are being performed, and Organon and Daré are working towards a 2023 U.S. launch as soon as feasible.
Cautionary
Statement Regarding Forward-Looking Statements
Daré
cautions you that all statements, other than statements of historical facts, contained in this report, are forward-looking statements.
Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,”
“contemplate,” “project,” “target,” “objective,” or the negative version of these words
and similar expressions. In this report, forward-looking statements include, but are not limited to, statements relating to Daré’s
expectations about timing of commercial availability of XACIATO in the United States. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially
different from those expressed or implied by the forward-looking statements, including, without limitation: the risks that none of the
milestones under the agreement with Organon may be achieved; dependence on Organon to commercialize licensed products and on other third
parties for commercial supplies of licensed products and components and Daré’s lack of control over the efforts and resources
expended by those third parties; Daré’s ability to raise additional capital when and as needed to support its operations,
execute its business strategy and continue as a going concern; general industry conditions and competition; and the effects of macroeconomic
conditions such as inflation, rising interest rates and geopolitical events on Daré’s operations, financial results and
condition, and ability to achieve current plans and objectives. Daré’s forward-looking statements are based upon its current
expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly
qualified in their entirety by these cautionary statements. For a detailed description of Daré’s risks and uncertainties,
you are encouraged to review its documents filed with the SEC including Daré’s recent filings on Form 8-K, Form 10-K and
Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they
were made. Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after
the date on which they were made, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
DARÉ
BIOSCIENCE, INC. |
|
|
Dated:
July 5, 2023 |
By: |
/s/
Sabrina Martucci Johnson |
|
Name: |
Sabrina
Martucci Johnson |
|
Title: |
President
and Chief Executive Officer |
Exhibit
99.1
![](https://www.sec.gov/Archives/edgar/data/1401914/000149315223023364/ex99-1_001.jpg)
Daré
Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved
Treatment for Females 12 and Older with Bacterial Vaginosis
Daré
to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license
agreement
SAN
DIEGO, July 5, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today
reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator
Organon (NYSE: OGN), and announced that Organon will pay Daré $1.0 million in July 2023.
“We
believe Organon’s commercial capabilities and track record of success in the branded women’s health category will help ensure
a successful introduction of XACIATO in the United States and, ultimately, that XACIATO reaches the global population of women suffering
from bacterial vaginosis, which is estimated to impact between 23% to 29% of all women worldwide,” said Sabrina Martucci Johnson,
President and CEO of Daré. “Daré has completed manufacturing validation activities required to support commercial
launch. To provide for continuity of supply to support a robust commercial launch, additional manufacturing related activities are being
performed and Organon and Daré are working towards a 2023 U.S. launch as soon as feasible. We are confident that XACIATO will
be well positioned for commercial success given the knowledge and experience of Organon’s sales team, which is the same sales team
that helped drive the market acceptance and record sales of NEXPLANON®, coupled with Organon’s payer outreach and provider
and patient-centered initiatives, and we look forward to the launch later this year.”
Under
the amended license agreement between Daré and Organon for XACIATO, Organon will pay Daré $1.0 million in July 2023 and
will pay Daré $1.8 million upon the first commercial sale of XACIATO. In 2022, Daré received a $10.0 million upfront payment
from Organon when the license agreement became effective. In addition to the upfront payment and the $2.8 million described above, Daré
is also eligible to receive additional potential future milestone payments of up to $180.0 million and tiered double-digit royalties
based on net sales.
As
Daré previously shared, the New Drug Application (NDA) for XACIATO was supported by positive results from the DARE-BVFREE
Phase 3 randomized, multi-center, double-blinded, placebo-controlled clinical trial evaluating XACIATO (formerly known as DARE-BV1) for
the treatment of bacterial vaginosis (NCT04370548).
About
Daré Bioscience
Daré
Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission
is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women’s health and
well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health,
menopause, sexual health and fertility.
Daré’s
first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment
of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO
is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s portfolio also includes
potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive
whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil
to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; and DARE-HRT1, a combination bio-identical estradiol
and progesterone intravaginal ring for menopausal hormone therapy. To learn more about XACIATO, Daré’s full portfolio of
women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit
www.darebioscience.com.
Daré
may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors
section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré
will use these channels to distribute material information about the company and may also use social media to communicate important information
about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts
on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors,
the media, and others interested in the company to review the information Daré posts in the Investors section of its website and
to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may
use to communicate information will be posted in the Investors section of Daré’s website.
Forward-Looking
Statements
Daré
cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.
Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,”
“contemplate,” “project,” “target,” “objective,” or the negative version of these words
and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to Daré’s
expectations about commercial distribution and sale of XACIATO, receipt of payments from Organon, and expected timing of commercial availability
of XACIATO in the United States. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may
cause Daré’s actual results, performance or achievements to be materially different from those expressed or implied by the
forward-looking statements in this press release, including, without limitation: the risks that none of the milestones under the agreement
with Organon may be achieved and none of potential milestone payments become payable; the potential for royalty payments to be subject
to reductions and offsets; dependence on Organon to commercialize licensed products and on other third parties for commercial supplies
of licensed products and components and Daré’s lack of control over the efforts and resources expended by those third parties;
Daré’s ability to raise additional capital when and as needed to support its operations, execute its business strategy and
continue as a going concern; general industry conditions and competition; the effects of macroeconomic conditions such as inflation,
rising interest rates and geopolitical events on Daré’s operations, financial results and condition, and ability to achieve
current plans and objectives; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally;
the risk that developments by competitors make Daré’s product or product candidates less competitive or obsolete; difficulties
establishing and sustaining relationships with development and/or commercial collaborators; failure of Daré’s product or
product candidates, if approved, to gain market acceptance or obtain adequate coverage or reimbursement from third-party payers; Daré’s
ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré’s ability to satisfy
the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents
and related intellectual property related to its product and product candidates; Daré’s ability to adequately protect or
enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain
of Daré’s product candidates which could expose its products to competition from other formulations using the same active
ingredients; product liability claims; governmental investigations or actions relating to Daré’s product or product candidates
or the business activities of Daré, its commercial collaborators or other third parties on which Daré relies; the impact
of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health
care cost containment; cyber-attacks, security breaches or similar events that compromise Daré’s technology systems or those
of third parties on which it relies and/or significantly disrupt Daré’s business; and disputes or other developments concerning
Daré’s intellectual property rights. Daré’s forward-looking statements are based upon its current expectations
and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified
in their entirety by these cautionary statements. For a detailed description of Daré’s risks and uncertainties, you are
encouraged to review its documents filed with the SEC including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.
Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date
on which they were made, except as required by law.
Contacts:
Investors
on behalf of Daré Bioscience, Inc.:
Lee
Roth
Burns
McClellan
lroth@burnsmc.com
646.930.4406
OR
Media
on behalf of Daré Bioscience, Inc.:
Jake
Robison
Evoke
Canale
jake.robison@evokegroup.com
619.849.5383
Source:
Daré Bioscience, Inc.
v3.23.2
Cover
|
Jul. 04, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jul. 04, 2023
|
Entity File Number |
001-36395
|
Entity Registrant Name |
Dare Bioscience, Inc.
|
Entity Central Index Key |
0001401914
|
Entity Tax Identification Number |
20-4139823
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
3655
Nobel Drive
|
Entity Address, Address Line Two |
Suite 260
|
Entity Address, City or Town |
San
Diego
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
92122
|
City Area Code |
(858)
|
Local Phone Number |
926-7655
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
stock
|
Trading Symbol |
DARE
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
Entity Information, Former Legal or Registered Name |
Not
Applicable
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2023 to Jul 2024